Vaxelis™

BIOLOGICAL2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Hexavalent VaccinePneumococcal InfectionsVaccines, Combined

Phase 3

Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)

CompletedNCT04016714

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2019-08-28End: 2021-10-29Updated: 2023-05-06

Phase 4

Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016)

CompletedNCT05289271

Merck Sharp & Dohme LLCHexavalent Vaccine, Vaccines, Combined

Start: 2022-03-25End: 2022-08-30Updated: 2024-07-29